Floatz logo

Psma-Hbed-Cc

Prostate Adenocarcinoma

Fred Hutchinson Cancer CenterradiopharmaceuticalPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
73/ 100

Competitive context

53 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Degarelix
Canadian Cancer Trials Group
Phase 3BB
LEUPROLIDE
Mayo Clinic
Phase 3BB
Zoladex
CancerCare Manitoba
Phase 3BB
Flutamide
NRG Oncology
Phase 3BB
PIFLUFOLASTAT
Sean Sachdev
Phase 4BB

View all 50 →

Same molecule, other indications

Psma-Hbed-Cc is also rated in:

Metastatic Prostate CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
Castration-Resistant Prostate CarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →